Gene screening and prevention of hereditary breast cancer: a cost-effectiveness Monte-Carlo study

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68407700%3A21460%2F13%3A00205725" target="_blank" >RIV/68407700:21460/13:00205725 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Gene screening and prevention of hereditary breast cancer: a cost-effectiveness Monte-Carlo study
Original language description
BACKGROUND: The hereditary syndrome (BRCA1/BRCA2 mutations) causes 5?7% of diagnosed breast cancer. In Czech Republic, patients suspected of this gene alteration undergo DNA testing, and the whole family joins screening programs. They will eventually become ill with a high probability (predicted breast cancer risk in women with BRCA1/BRCA2 mutation being 78-83% by the age of 70), however, the screening can detect cancer in earlier stages. The screening program has run only for 10 years comprising 105 patients, 10 diagnosed with breast cancer. Although the outcome in these women was better than in the general population, cost/QALY appeared higher for preventive programs. The reasons might have been the size of the sample. OBJECTIVE: To assess cost effectiveness of hereditary breast cancer prevention as standard care in family members of diagnosed patients. METHODS: Due to the lack of clinical data, calculations were repeated using a cohort of patients generated by the Monte-Carlo method
Czech name
—
Czech description
—

Project
<a href="/en/project/NT11532" target="_blank" >NT11532: Medical Technology Assessment</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2013
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)